Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

被引：4
|
作者：
Soumerai, Jacob D. [1 ]
Diefenbach, Catherine S. [2 ]
Samaniego, Felipe [3 ]
Kumar, Abhijeet [4 ]
Tsai, Michaela L. [5 ]
Asch, Adam S. [6 ]
Jagadeesh, Deepa [7 ]
Kenkre, Vaishalee P. [8 ]
Lossos, Izidore S. [9 ]
Salman, Huda [10 ]
Awan, Farrukh T. [11 ]
Miao, Lu [12 ]
Ghalie, Richard G. [12 ]
Zelenetz, Andrew D. [13 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Lymphoma, Boston, MA 02114 USA
[2] NYU, Sch Med, NYU Canc Inst, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[4] Univ Arizona, Ctr Canc, Div Hematol & Oncol, Tucson, AZ USA
[5] Swedish Canc Inst, Seattle, WA USA
[6] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[7] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Stony Brook Univ Hosp, Stony Brook, NY USA
[11] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[12] MEI Pharma Inc, San Diego, CA USA
[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157563
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.
    Soumerai, Jacob Drobnyk
    Jagadeesh, Deepa
    Salman, Huda S.
    Lossos, Izidore S.
    Asch, Adam Steven
    Reddy, Nishitha
    Kenkre, Vaishalee Padgaonkar
    Pagel, John M.
    Persky, Daniel O.
    Awan, Farrukh Tauseef
    Diefenbach, Catherine S. Magid
    Huang, Wenying
    Llorin-Sangalang, Judith
    Gorbatchevsky, Igor
    Zelenetz, Andrew David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma
    Weaver, A. N.
    Jimeno, A.
    DRUGS OF TODAY, 2020, 56 (08) : 531 - 539
  • [3] Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).
    Zelenetz, Andrew David
    Jagadeesh, Deepa
    Reddy, Nishitha M.
    Stathis, Anastasios
    Salman, Huda S.
    Asch, Adam Steven
    Kenkre, Vaishalee Padgaonkar
    Jhangiani, Haresh S.
    Iasonos, Alexia
    Soumerai, Jacob D.
    Llorin, Judith
    Pagel, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
    Kahl, Brad S.
    Spurgeon, Stephen E.
    Furman, Richard R.
    Flinn, Ian W.
    Coutre, Steven E.
    Brown, Jennifer R.
    Benson, Don M.
    Byrd, John C.
    Peterman, Sissy
    Cho, Yoonjin
    Yu, Albert
    Godfrey, Wayne R.
    Wagner-Johnston, Nina D.
    BLOOD, 2014, 123 (22) : 3398 - 3405
  • [5] Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
    McCulloch, Rory
    Visco, Carlo
    Eyre, Toby A.
    Frewin, Rebecca
    Phillips, Neil
    Tucker, David L.
    Quaglia, Francesca M.
    McMillan, Annabel
    Lambert, Jonathan
    Crosbie, Nicola
    Rule, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 684 - 688
  • [6] Efficacy of R-BAC immunochemotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
    McCulloch, R.
    Frewin, R.
    Tucker, D.
    Kerr, J. P.
    Phillips, N.
    Gandla, J.
    Crosbie, N.
    Lewis, D.
    Rule, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 88 - 88
  • [7] Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Shah, Bijal
    Challagulla, Swetha
    Xu, Sheng
    Williams, Rhys
    Ren, Shijie
    Srivastava, Tushar
    Gautam, Raju
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S516 - S517
  • [8] The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Pagel, John
    Zelenetz, Andrew
    Reddy, Nishitha
    Jagadeesh, Deepa
    Stathis, Anastasios
    Salman, Huda
    Soumerai, Jacob
    Kenkre, Vaishalee
    Asch, Adam
    Jhangiani, Haresh
    Llorin-Sangalang, Judith
    Wood, Jamie
    Gorbatchevsky, Igor
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S32 - S32
  • [9] The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
    Zelenetz, Andrew D.
    Jurczak, Wojciech
    Ribrag, Vincent
    Linton, Kim
    Collins, Graham P.
    Jimenez, Javier L.
    Bishton, Mark
    Dholaria, Bhagirathbhai
    Mengarelli, Andrea
    Phillips, Tycel J.
    Sungala, Nagendraprasad
    Musuraca, Gerardo
    Sheehy, Oonagh
    Van Den Neste, Eric
    Odera, Mitsuhiko
    Miao, Lu
    Gold, Daniel P.
    Ghalie, Richard G.
    Zinzani, Pier L.
    HEMASPHERE, 2024, 8 (08):
  • [10] Pirtobrutinib in covalent BTK-inhibitor pre- treated relapsed/refractory (R/R) Mantle Cell Lymphoma
    Fileni, Caroline
    Sarkozy, Clementine
    BULLETIN DU CANCER, 2023, 110 (10) : 988 - 990
12345